Section I
31 – 40 of 4690
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Outcomes for patients with secondary CNS involvement in relapsed/refractory diffuse large B-cell lymphoma and estimation of eligibility for CAR T-cell therapy
(
- Contribution to journal › Letter
-
Mark
Tattoos as a risk factor for malignant lymphoma: a population-based case–control study
(
- Contribution to journal › Article
-
Mark
Morbiditet från urinvägar och tarm enligt registerdata efter ultrahypofraktionerad strålbehandling för lokaliserad prostatacancer vid 10 år i HYPO-RT-PC-studien
2024) Onkologidagarna 2024(
- Contribution to conference › Poster
-
Mark
Register data on long-term morbidity after prostate ultra-hypofractionation in the HYPO-RT-PC trial
(
- Contribution to conference › Abstract
-
Mark
Risk of prostate cancer death in men diagnosed with prostate cancer at cystoprostat-ectomy. A nationwide population-based study
(
- Contribution to journal › Article
-
Mark
Precision Medicine in Breast Cancer: A Molecular Genomics and Diagnostics Approach
2024) In Lund University, Faculty of Medicine Doctoral Dissertation Series(
- Thesis › Doctoral thesis (compilation)
-
Mark
Metabolic and angiogenic biomarkers in breast cancer: potential clinical implications of host–tumor interactions
2024) In Lund University, Faculty of Medicine Doctoral Dissertation Series(
- Thesis › Doctoral thesis (compilation)
-
Mark
Real-World Treatment Patterns and Survival Outcomes for Patients with Non-Metastatic Non-Small-Cell Lung Cancer in Sweden : A Nationwide Registry Analysis from the I-O Optimise Initiative
(
- Contribution to journal › Article
-
Mark
Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE) : a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network
(
- Contribution to journal › Article
-
Mark
Quality assessment of radiotherapy in the prospective randomized SENOMAC trial
(
- Contribution to journal › Article